{"disease":{"id":"prevention-of-covid-19-in-individuals-12-years-of-age-and-older-who-have-previously-received-a-booster-dose-of-any-authorized-covid-19-vaccine","name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","indication_name":"Prevention of COVID-19 in individuals 12 years of age and older who have previously received primary vaccination with any authorized COVID-19 vaccine and have previously received a booster dose of any authorized COVID-19 vaccine","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose","generic_name":"variant-adapted-bnt162b2-omicron-xbb-1-5-3-microgram-dose","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}